FULC - Fulcrum Therapeutics, Inc.

QQQ $ 451.24 $ 2.32 (0.52 %)

DIA $ 398.54 $ 0.66 (0.17 %)

SPY $ 528.56 $ 2.61 (0.5 %)

TLT $ 92.22 $ 0.39 (0.42 %)

GLD $ 220.66 $ 1.42 (0.65 %)

Previous Close

$ 7.91

Open

$ 8.31

Bid

$ 0.00 x 0

Ask

$ 8.52 x 100

Day's Range

$ 8.10 - $ 8.69

52 Week Range

$ 2.65 - $ 13.70

Volume

1,114,359

Average Volume

Market Cap

490.29M

Beta (5Y Monthly)

$ 1.55

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-13-2024	03-31-2024	10-Q
2	02-27-2024	12-31-2023	10-K
3	11-07-2023	09-30-2023	10-Q
4	08-03-2023	06-30-2023	10-Q
5	05-15-2023	03-31-2023	10-Q
6	03-09-2023	12-31-2022	10-K
7	11-08-2022	09-30-2022	10-Q
8	08-11-2022	06-30-2022	10-Q
9	05-09-2022	03-31-2022	10-Q
10	03-03-2022	12-31-2021	10-K
11	11-04-2021	09-30-2021	10-Q
12	08-10-2021	06-30-2021	10-Q
13	05-06-2021	03-31-2021	10-Q
14	03-04-2021	12-31-2020	10-K
15	11-10-2020	09-30-2020	10-Q
16	08-11-2020	06-30-2020	10-Q
17	05-13-2020	03-31-2020	10-Q
18	03-05-2020	12-31-2019	10-K
19	11-14-2019	09-30-2019	10-Q
20	08-26-2019	06-30-2019	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Goldman Sachs Upgrades Fulcrum Therapeutic...
05/14/2024 12:40:06

Goldman Sachs analyst Corinne Jenkins upgrades Fulcrum Therapeutics (NASDAQ:FULC) from Neutral to Buy and raises the price t...

HC Wainwright & Co. Reiterates Buy on Fulc...
05/14/2024 11:09:55

HC Wainwright & Co. analyst Andrew Fein reiterates Fulcrum Therapeutics (NASDAQ:FULC) with a Buy and maintains $17 price...

Oppenheimer Maintains Outperform on Fulcru...
05/14/2024 09:21:07

Oppenheimer analyst Matthew Biegler maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Outperform and lowers the price targ...

Deep Dive Into Fulcrum Therapeutics Stock:...
05/13/2024 21:01:14

Goldman Sachs Upgrades Fulcrum Therapeutic...
05/13/2024 20:22:24

Goldman Sachs analyst Corinne Jenkins upgrades Fulcrum Therapeutics (NASDAQ:FULC) from Neutral to Buy and announces $15 pric...

12-health-care-stocks-moving-in-mondays-pre-market-session

12 Health Care Stocks Moving In Monday's P...
05/13/2024 12:06:42

Fulcrum Therapeutics Expects Cash Balance ...
05/13/2024 11:05:06

Fulcrum Therapeutics Q1 2024 GAAP EPS $(0....
05/13/2024 11:01:57

Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of ...

Fulcrum Therapeutics Announces License Agr...
05/13/2024 10:04:22

― Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. c...

Fulcrum Therapeutics Announces Publication...
05/08/2024 12:13:43

― Phase 2b ReDUX4 clinical trial indicates improvements in functional, structural, and patient-reported outcomes; findings info...

10-health-care-stocks-whale-activity-in-todays-session

10 Health Care Stocks Whale Activity In To...
03/29/2024 17:35:25

RBC Capital Initiates Coverage On Fulcrum ...
03/13/2024 16:31:28

RBC Capital analyst Gregory Renza initiates coverage on Fulcrum Therapeutics (NASDAQ:FULC) with a Outperform rating and anno...

Why United Natural Foods Shares Are Tradin...
03/06/2024 18:54:52

Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.

Box Reports Upbeat Earnings, Joins America...
03/06/2024 16:45:28

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday.

Deep Dive Into Fulcrum Therapeutics Stock:...
02/28/2024 20:00:51

HC Wainwright & Co. Maintains Buy on Fulcr...
02/28/2024 18:13:27

HC Wainwright & Co. analyst Andrew Fein maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Buy and raises the price tar...

Piper Sandler Maintains Overweight on Fulc...
02/28/2024 15:44:13

Piper Sandler analyst Edward Tenthoff maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight and raises the price ta...

Fulcrum Therapeutics Q4 GAAP EPS $(0.40) B...
02/27/2024 12:08:34

Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of ...

Earnings Scheduled For February 27, 2024
02/27/2024 10:01:31

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on rev...

Earnings Preview: Fulcrum Therapeutics
02/26/2024 20:01:56